Recent News Subscribe
-
Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2009 Results on February 11, 2010
Thursday, Jan 28, 2010
CHESHIRE, Conn., Jan 28, 2010 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will report its financial results for the fourth quarter and year ended December 31, 2009 on Thursday, February 11, 2010 before the financial markets open. Following the release of the financial res...
-
Alexion to Present at the 28th Annual JP Morgan Healthcare Conference
Wednesday, Jan 6, 2010
CHESHIRE, Conn., Jan 06, 2010 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the 28th Annual JP Morgan Healthcare Conference in San Francisco at 3:00 p.m. local time (6:00 p.m. Eastern) on Wednesday, ...
-
Soliris(R) Reduced Hemolysis, Lowered Thrombosis Rate and Improved Quality of Life in Patients with PNH Who Had Previously Never Been Transfused
Monday, Dec 7, 2009
CHESHIRE, Conn., Dec 07, 2009 (BUSINESS WIRE) -- New data presented today demonstrate the severe clinical burden of paroxysmal nocturnal hemoglobinuria (PNH) and the clinical benefits of Soliris(R) (eculizumab) in 44 patients with no history of prior blood transfusions. Prior to Soliris treatment, these never-transfused ...
-
Soliris<font size="-1"><sup>®</sup></font> Reversed Thrombocytopenia in Patients with Both PNH and Pre-Existing Thrombocytopenia in Study Presented at ASH Annual Meeting
Monday, Dec 7, 2009
CHESHIRE, Conn., Dec 07, 2009 (BUSINESS WIRE) -- Soliris<font size="-1"><sup>®</sup></font> (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), reversed thrombocytopenia (abnormally low platelet count) in a significant proportion of patients ...
-
Soliris(R) Reduced Hemolysis, Decreased Transfusion Requirements and Improved Fatigue in Patients with PNH and Bone Marrow Insufficiency Disorders
Sunday, Dec 6, 2009
CHESHIRE, Conn., Dec 06, 2009 (BUSINESS WIRE) -- Soliris(R) (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), reduced hemolysis (destruction of red blood cells) and transfusion requirements, and improved measures of fatigue, when added to o...
-
Researchers Report Clinical Association Between Type II PNH Cells and Thrombocytopenia
Sunday, Dec 6, 2009
CHESHIRE, Conn., Dec 06, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced presentation of data showing that the presence of Type II paroxysmal nocturnal hemoglobinuria (PNH) cells is correlated with thrombocytopenia, potentially indicating that patients with Type II cells e...
-
Long-Term Soliris(R) Treatment Resulted in Sustained Reduction in Hemolysis and Improved Kidney Function in Japanese Patients with PNH
Saturday, Dec 5, 2009
CHESHIRE, Conn., Dec 05, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris(R) (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglo...
-
Alexion Reports Progress on Commissioning of Rhode Island Manufacturing Facility as Second Source of Supply
Wednesday, Dec 2, 2009
CHESHIRE, Conn., Dec 02, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today provided updates on the regulatory review and approval, or commissioning, of Alexion's Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of supply for Soliris(R) (eculizumab). The ...
-
Alexion Appoints William R. Keller to its Board of Directors
Tuesday, Dec 1, 2009
CHESHIRE, Conn., Dec 01, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Mr. William R. Keller has been appointed a Director of Alexion, effective immediately. With Mr. Keller's appointment, there are now eight members of Alexion's Board of Directors. About William KellerMr. Keller ...
-
Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Wednesday, Nov 11, 2009
CHESHIRE, Conn., Nov 11, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Lazard Capital Markets 6th Annual Healthcare Conference in New York City at 10:00 a.m. ET on Wednesday, November 18, ...
-
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the ASH Annual Meeting
Tuesday, Nov 10, 2009
CHESHIRE, Conn., Nov 10, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data relating to Soliris(R) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Soc...
-
Alexion to Present at Credit Suisse's 2009 Healthcare Conference
Thursday, Nov 5, 2009
CHESHIRE, Conn., Nov 05, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Credit Suisse's 2009 Healthcare Conference in Phoenix, Arizona at 8:00 a.m., local time (10:00 a.m. ET) on Thursday, November...
-
Alexion to Present at the Oppenheimer 20th Annual Healthcare Conference
Wednesday, Oct 28, 2009
CHESHIRE, Conn., Oct 28, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Oppenheimer 20th Annual Healthcare Conference in New York City at 3:55 p.m. ET on Wednesday, November 4, 2009. An audio ...
-
Alexion Reports Third Quarter 2009 Results
Thursday, Oct 22, 2009
CHESHIRE, Conn., Oct 22, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company," NASDAQ: ALXN) today announced financial results for the quarter ended September 30, 2009. Third Quarter 2009 Financial Results:For the three months ended September 30, 2009, Alexion reported total revenues of $102.6 m...
-
Alexion Pharmaceuticals to Report Third Quarter 2009 Results on October 22, 2009
Monday, Oct 12, 2009
CHESHIRE, Conn., Oct 12, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will report its financial results for the third quarter ended September 30, 2009 on Thursday, October 22, 2009 before the financial markets open. Following the release of the financial results, Alex...
-
Alexion to Present at the UBS Global Life Sciences Conference
Wednesday, Sep 16, 2009
CHESHIRE, Conn., Sep 16, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the UBS Global Life Sciences Conference in New York City at 3:30 p.m. ET on Tuesday, September 22, 2009. An audio webcast of...
-
Alexion to Present at Investor Conferences
Tuesday, Sep 8, 2009
CHESHIRE, Conn., Sep 08, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Mr. Vikas Sinha, Chief Financial Officer of Alexion, will present at the Thomas Weisel Partners Healthcare Conference 2009 in Boston on Friday, Sept...
-
European Commission and U.S. FDA Grant Alexion's Soliris<font size="-1"><sup>®</sup></font> (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)
Thursday, Aug 6, 2009
CHESHIRE, Conn., Aug 06, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that Soliris(R) (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syn...
-
Alexion Reports Second Quarter 2009 Results
Thursday, Jul 23, 2009
CHESHIRE, Conn., Jul 23, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the quarter ended June 30, 2009. Second Quarter 2009 Financial Results:For the three months ended June 30, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported total revenues of $9...
-
Alexion Pharmaceuticals to Report Second Quarter 2009 Results on July 23, 2009
Thursday, Jul 9, 2009
CHESHIRE, Conn., Jul 09, 2009 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will report its financial results for the second quarter ended June 30, 2009 on Thursday, July 23, 2009 before the financial markets open. Following the release of the financial results, Alexion man...